LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest ...
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price ...
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...
Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...
Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing ...
Investing.com -- Keros Therapeutics, Inc. (NASDAQ: KROS) shares rose 6% following the announcement of the effectiveness of its global license agreement with pharmaceutical giant Takeda. The deal, ...
Keros Therapeutics Inc (KROS) stock saw a decline, ending the day at $11.39 which represents a decrease of $-0.02 or -0.18% from the prior close of $11.41. The stock opened at $11.31 and touched a low ...
Keros Therapeutics (KROS) stock rises as a licensing deal with Takeda (TAK) begins. However, Cantor Fitzgerald downgrades, citing a trial setback. Read more here.
On Tuesday, Keros Therapeutics (NASDAQ:KROS) faced a downgrade in stock rating from Buy to Neutral by Cantor Fitzgerald. The stock, which has declined nearly 80% over the past year according to ...
Keros Therapeutics Inc (KROS) stock saw a modest uptick, ending the day at $10.86 which represents a slight increase of $0.34 or 3.23% from the prior close of $10.52. The stock opened at $11 and ...